BNP Paribas Financial Markets
PVLA

BNP Paribas Financial Markets’s Palvella Therapeutics PVLA Stock Holding History

BNP Paribas Financial Markets’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$787K Sell
5,151
-22,630
-81% -$2.75M ﹤0.01% 3481
2026
Q1 		$3.46M Buy
27,781
+27,311
+5,811% +$2.85M ﹤0.01% 2302
2025
Q4 		$49.2K Sell
470
-934
-67% -$79.7K ﹤0.01% 4692
2025
Q3 		$88K Sell
1,404
-3,226
-70% -$144K ﹤0.01% 4353
2025
Q2 		$104K Buy
+4,630
New +$109K ﹤0.01% 4003
2022
Q2 		– Sell
-405
Closed -$98.1K – 4288
2022
Q1 		$98.1K Sell
405
-2,723
-87% -$716K ﹤0.01% 3363
2021
Q4 		$946K Buy
3,128
+3,117
+28,336% +$998K ﹤0.01% 2632
2021
Q3 		$4.36K Sell
11
-3
-21% -$1.04K ﹤0.01% 3720
2021
Q2 		$4.16K Sell
14
-79
-85% -$17.3K ﹤0.01% 3814
2021
Q1 		$19.1K Sell
93
-65
-41% -$14.2K ﹤0.01% 3766
2020
Q4 		$31.6K Sell
158
-16
-9% -$3.33K ﹤0.01% 3732
2020
Q3 		$28.7K Buy
174
+151
+657% +$34.4K ﹤0.01% 3703
2020
Q2 		$5.83K Sell
23
-173
-88% -$40.5K ﹤0.01% 3939
2020
Q1 		$35.7K Buy
196
+108
+123% +$27.2K ﹤0.01% 3711
2019
Q4 		$25.4K Sell
88
-16
-15% -$4.44K ﹤0.01% 3936
2019
Q3 		$28.3K Buy
104
+25
+32% +$9.68K ﹤0.01% 3791
2019
Q2 		$29.8K Sell
79
-56
-41% -$16.7K ﹤0.01% 3734
2019
Q1 		$36.2K Buy
+135
New +$32.1K ﹤0.01% 3683
2018
Q4 		– Sell
-21
Closed -$9.2K – 4445
2018
Q3 		$9.2K Hold
21
– – ﹤0.01% 3775
2018
Q2 		$8.46K Sell
21
-93
-82% -$44.3K ﹤0.01% 3857
2018
Q1 		$62.2K Buy
114
+17
+18% +$10.5K ﹤0.01% 3439
2017
Q4 		$58.3K Buy
97
+55
+131% +$25.6K ﹤0.01% 3582
2017
Q3 		$19.3K Sell
42
-3
-7% -$1.28K ﹤0.01% 3609
2017
Q2 		$18.2K Buy
+45
New +$13.2K ﹤0.01% 3713

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BNP Paribas Financial Markets's PVLA Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Palvella Therapeutics (PVLA) stake by 81% in Q2 2026, selling an estimated $2.75M and leaving 5,151 shares worth $787K. The position accounts for ﹤0.01% of the portfolio, ranked #3481.

BNP Paribas Financial Markets first reported a position in PVLA in Q2 2017 and has held it in 24 quarters since. The position peaked at $3.46M in Q1 2026. 181 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • BNP Paribas Financial Markets held 5,151 shares of Palvella Therapeutics worth $787K as of Q2 2026.
  • BNP Paribas Financial Markets sold 22,630 Palvella Therapeutics shares in Q2 2026, an estimated $2.75M.
  • Palvella Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3481 holding.
  • BNP Paribas Financial Markets first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 24 quarters since.
  • BNP Paribas Financial Markets's Palvella Therapeutics position peaked at $3.46M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.